Economics of stratified medicine in rheumatoid arthritis.

about

The challenging interplay between rheumatoid arthritis, ageing and comorbidities.A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice

P2860

Q36000249-7502613D-D5CE-4CED-986C-32F191C0D65F Q37484873-35350A1B-BEC6-475A-9522-923A1A7DC37C

P2860

Economics of stratified medicine in rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38264743

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Economics of stratified medicine in rheumatoid arthritis.

@en

type

Item

label

Economics of stratified medicine in rheumatoid arthritis.

@en

prefLabel

Economics of stratified medicine in rheumatoid arthritis.

@en

P1476

Economics of stratified medicine in rheumatoid arthritis.

@en

P2093

Andrea Manca

http://www.w3.org/2001/XMLSchema#string

Cynthia Iglesias

http://www.w3.org/2001/XMLSchema#string

P2860

Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.

Understanding why rheumatoid arthritis patient treatment preferences differ by race.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Treating rheumatoid arthritis to target: recommendations of an international task force.

Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register.

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

Patient preferences for treatment of rheumatoid arthritis.

Economic considerations for health insurance coverage of emerging genetic tests.

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions.

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.

P2888

s11926-014-0468-x

P304

468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-014-0468-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044105594

http://www.w3.org/2001/XMLSchema#string

P698

25366935

http://www.w3.org/2001/XMLSchema#string

Economics of stratified medicine in rheumatoid arthritis.

about

P2860

P2860

Economics of stratified medicine in rheumatoid arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698